Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 10/20 | 0.62 |
| ▸ | CA2 | P00918 | 2/20 | 0.62 |
| ▸ | DDB1 | Q16531 | 8/20 | 0.61 |
| ▸ | STAT3 | P40763 | 6/20 | 0.60 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.56 |
| ▸ | NCOR2 | Q9Y618 | 3/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29986699 | 1.00 | CRBN (0.62) | CRBNCA2DDB1STAT3HDAC3 | |
| SCHEMBL25204590 | 0.96 | CRBN (0.64) | CRBNCA2DDB1STAT3HDAC3 | |
| SCHEMBL29986813 | 0.96 | CRBN (0.64) | CRBNCA2DDB1STAT3HDAC3 | |
| SCHEMBL24745682 | 0.94 | CRBN (0.66) | CRBNCA2DDB1STAT3HDAC3 | |
| SCHEMBL30000878 | 0.94 | CRBN (0.66) | CRBNCA2DDB1STAT3HDAC3 | |
| SCHEMBL24418634 | 0.93 | CRBN (0.65) | CRBNCA2DDB1STAT3 | |
| SCHEMBL29877119 | 0.92 | CRBN (0.61) | CRBNCA2DDB1STAT3HDAC3 | |
| SCHEMBL30000661 | 0.91 | CRBN (0.63) | CRBNCA2DDB1STAT3 | |
| SCHEMBL19475706 | 0.90 | STAT3 (0.64) | CRBNCA2DDB1STAT3 | |
| SCHEMBL19508773 | 0.90 | STAT3 (0.64) | CRBNCA2DDB1STAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167105-A1 | BCL-2 PROTEIN INHIBITORS | RECURIUM IP HOLDINGS, LLC | 2023-06-01 | — | — | US | disclosed |
| CN-115461335-A | BCL-2 protein inhibitors | 里科瑞尔姆IP控股有限责任公司 | 2022-12-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167105-A1 | BCL-2 PROTEIN INHIBITORS | BCL2, BCL2L1, BCL2L2 | CRBN 325/4885CA2 1299/4885DDB1 181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.